阿培利司减少先天性黑色素细胞痣的痣细胞
该研究利用10例先天性黑色素细胞痣(CMN)患者的新鲜组织样本进行体外器官培养,分别在有或无阿培利司的条件下培养5天。结果显示,阿培利司处理组细胞密度、SOX10阳性细胞密度及S-100阳性面积百分比均显著降低,提示阿培利司可减少CMN中的痣细胞。
要点
- 阿培利司处理可显著降低CMN组织中的细胞密度。
- 阿培利司处理可显著降低SOX10阳性细胞密度和S-100阳性面积百分比。
- 三种标志物的降低呈正相关,提示阿培利司可能减少痣细胞。
核心结论
- 首次提供证据表明阿培利司可在患者来源的CMN外植体中诱导痣细胞减少,可能由自噬介导。
研究设计与样本
- 前瞻性收集10例CMN患者的新鲜痣组织样本,采用先前报道的离体器官培养模型,培养5天,分别设置阿培利司处理组和对照组。
主要发现
- 与对照组相比,阿培利司处理组细胞密度降低(p=0.0273)。
- 阿培利司处理组SOX10阳性细胞密度降低(p=0.0391)。
- 阿培利司处理组S-100阳性面积百分比降低(p=0.0078)。
- 三种标志物的变化呈正相关(p<0.05)。
临床怎么用
- 阿培利司是已获批用于PIK3CA相关过度生长谱(PROS)严重表现患者的PI3K抑制剂,安全性良好。
- 本研究为离体实验,临床用于CMN治疗前仍需进一步研究评估局部或全身给药的有效性。
局限性
- 样本量较小(10例),仅进行离体器官培养5天,需进一步体内研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple, large or giant congenital melanocytic nevi (CMN) are uncommon and affected patients can show progressive growth and thickening, associate neurocutaneous melanocytosis or develop melanoma. Current treatment modalities are mostly complex surgeries that frequently do not solve the disease and its risks completely. Thus, investigation on new treatment options for CMN and its complications must continue. MAPK pathway inhibitors are being investigated, also targeting PI3K-AKT. Omipalisib (PI3K inhibitor, with no indications approved yet) has been studied for CMN in vitro and in mice with promising results. However, alpelisib, a PI3K inhibitor approved with an adequate safety profile for patients with severe manifestations of PROS (PIK3CA-Related Overgrowth Spectrum), had not yet been tested for CMN. OBJECTIVE: To evaluate the effect of alpelisib in nevocytes of congenital melanocytic nevi. METHODS: Nevomelanocytic tissue samples of 10 patients were collected prospectively and, following a previously reported preclinical ex vivo model, explants were placed in organotypic culture for 5 days, with or without alpelisib. Consecutively, tissue sections were stained and using scanned images with Qupath and ImageJ softwares, representative regions from the dermis were analysed (using Wilcoxon test and Spearman's correlation). RESULTS: When comparing alpelisib-treated explants with respect to control explants, we found a decrease in cell density (p = 0.0273), in density of SOX10+-cells (p = 0.0391) and also in the % of S-100+ area (p = 0.0078), in alpelisib samples. The three markers showed a positive correlation (p < 0.05). CONCLUSIONS: This study provides first-time evidence that alpelisib induces nevocyte reduction in CMN from patient-derived explants, probably inducted by autophagy. Alpelisib is an approved drug with an adequate safety profile used in another mosaicism affecting PI3K (PROS). Further studies are needed to evaluate its efficacy in treating CMN and potentially, their complications, either with local or systemic administration, alone or in combination.
引用
- Tomás-Velázquez A, López-Gutiérrez JC, de Andrea C, et al. Alpelisib decreases nevocytes of congenital melanocytic nevi. J Eur Acad Dermatol Venereol. 2023. PMID: 38071601. doi:10.1111/jdv.19736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。